CT-POINT72
Point72 Asset Management (Point72), the family office managing the assets of investor and philanthropist Steve Cohen, is expanding its groundbreaking Point72 Academy Program to recruit students internationally from Asia and Europe and expects to add up to 15 students to its full-time Financial Analyst and Summer Analyst programs in 2017.
The Academy is Point72’s one-of-a-kind initiative to recruit and train new college graduates as long/short (L/S) equities investment professionals on an accelerated schedule. During the 12 month Financial Analyst program, Academy members spend more than 2,500 hours learning to create and refine financial models, conduct primary research, prepare stock recommendations and effectively convey their ideas.
“The Point72 Academy has transformed the way we hire and prepare young investor talent,” said Jaimi Goodfriend, Academy Director. “We were blown away and, frankly, humbled by the talent and success of our first Academy class. We have successfully added each graduate from the Class of 2015 to our investment platform. I am excited to work with our 2016 class and really looking forward to working with our international students when they arrive in 2017.”
“The Firm’s decision to further invest in the Academy Program by recruiting students internationally supports our aggressive growth strategy in Asia and Europe and helps us to capture multicultural talent that is critical to adding diversity of thought,” said Marc Desmidt, Chief Executive Officer of Point72’s international business. Under the oversight of Desmidt, Point72 has doubled the size of its workforce in London and recently hired 31 people for its Hong Kong, Singapore and Tokyo offices in the first eight months of 2016.
“We can teach young talent Point72’s way of investing in the US and then provide them the opportunity to work directly with a portfolio manager in their local region,” added Desmidt.
The first Academy class to complete the program, the Class of 2015, graduated this past summer. The second Academy class, the Class of 2016, began its course of study a month ago and the expanded international seats will be part of the third class, the Class of 2017.
The Class of 2016 has 12 full-time participants, including two women, up from no women in the first class. It includes graduates with a diverse set of majors in Music, Applied Mathematics, International Studies, Neuroscience, Environmental Science, Engineering, Business, and others.
The Academy also conducts a Summer Analyst Program, a 10-week preview of the Financial Analyst program available to students before they begin their final year of undergraduate study. More than 70% of the participants in the 2016 Summer Analyst program received offers to return full-time and 100% of these Summer Analysts accepted.
The Summer Analyst Program is just one part of Point72’s larger recruitment arc that starts with its annual Global Case Competition and the Sophomore Summit, a day-long learning event for remarkable second-year students.
Point72 has already received more than 4,600 applications for the 2017 Academy Program and applications will remain open through October. Applications received thus far for the 2017 Academy Program are up from 400 applications for the 2015 class and more than 3,200 applications in total for the 2016 class. A quarter of the 2017 applications are from international students.
Once the Class of 2017 Academy members complete their eight months of intensive training in the US, they will work directly with Point72 L/S investment professionals around the globe. This will be the first class that will rotate among Point72’s offices in London, Hong Kong, Singapore, Tokyo, New York and Stamford, Connecticut.
After the rotational period, they will be assigned to work full-time with L/S investment teams in their local region. They are paid during the training period and receive visa sponsorship.
The deadline for applications for Asian and European students is October 16, 2016 and October 23, 2016, respectively. To find out more about Point72 or to apply online, please visit: www.point72.com/academy .
About Point72 Asset Management
Point72 Asset Management is a family office managing the assets of its founder, Steven A. Cohen, and eligible employees. Point72 primarily invests in discretionary long/short equities and makes significant quantitative and macro investments. The Firm's long/short investment divisions are Point72 Asset Management and EverPoint Asset Management. Cubist Systematic Strategies is its quantitative business. The Firm is headquartered in Stamford, Connecticut, and maintains offices in New York, London, Hong Kong, Tokyo, and Singapore. Point72 Asset Management, L.P. is a family office and does not seek, solicit or accept any external investments. www.Point72.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160929005323/en/
Contact:
Media:
Point72 Asset Management
Jessica Schaefer, 203-890-3867
Jessica.Schaefer@Point72.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom